ABIVAX Société Anonyme Dividends and Buybacks

Dividend criteria checks 0/6

ABIVAX Société Anonyme does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-11.5%

Buyback Yield

Total Shareholder Yield	-11.5%
Future Dividend Yield	0%
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Seeking Alpha • Jun 02

Abivax: M&A Premium Vanishes After Obefazimod Phase 3 Safety Signal

Summary ABIVAX Société Anonyme shares plunged after Phase 3 obefazimod maintenance data in ulcerative colitis, despite meeting all efficacy endpoints. Safety concerns, particularly malignancy clustering at the 50 mg dose, overshadowed strong efficacy and may prompt regulatory scrutiny. My DCF model now values ABVX at $95.81/share, reflecting an increased probability of success, but commercial expectations remain high. I maintain a Hold rating for ABVX stock, as valuation already prices in robust execution, and further downside risk exists from safety and capital-raising uncertainties. Read the full article on Seeking Alpha

Seeking Alpha • Mar 27

ABIVAX: Undercovered, Late-Stage French Company With Upcoming Catalysts

Summary ABIVAX is a French company that IPO-ed in the US in 2023 and is running a phase 3 trial for ulcerative colitis. Their lead candidate, obefazimod, is in phase 3 trials for moderate to severe ulcerative colitis and has a novel mechanism of action. The company faces competition from other approved treatments for ulcerative colitis, but their drug has shown promising efficacy and a good safety profile. Read the full article on Seeking Alpha

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ABVX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABVX's dividend payments have been increasing.

Dividend Yield vs Market

ABIVAX Société Anonyme Dividend Yield vs Market

How does ABVX dividend yield compare to the market?
Segment	Dividend Yield
Company (ABVX)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.3%
Industry Average (Biotechs)	2.4%
Analyst forecast (ABVX) (up to 3 years)	0%

Notable Dividend: Unable to evaluate ABVX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABVX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ABVX's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ABVX has not reported any payouts.

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/03 13:25
End of Day Share Price	2026/06/03 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ABIVAX Société Anonyme is covered by 21 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Etzer Darout	Barclays
Julian Harrison	BTIG
Jason Butler	Citizens JMP Securities, LLC

ABIVAX Société Anonyme Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Abivax Reports Landmark Phase 3 Abtect Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Abivax: M&A Premium Vanishes After Obefazimod Phase 3 Safety Signal

ABIVAX Société Anonyme, Annual General Meeting, May 11, 2026

ABIVAX Société Anonyme Announces Board and Management Changes

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease At Ecco 2026

ABIVAX Société Anonyme to Report First Half, 2026 Results on Sep 14, 2026

ABIVAX Société Anonyme to Report Fiscal Year 2025 Results on Mar 23, 2026

Abivax SA Presents 22 Abstracts On Obefazimod In Inflammatory Bowel Disease At ECCO 2026 Including Oral Presentation On Preclinical Anti-Fibrotic Findings

Abivax SA Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of $649.984 million.

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of $400 million.

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, Its First-In-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis

Abivax Sa Announces Completion of Enrollment for the Phase 3 Abtect Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Abivax SA Appoints Dominik Höchli to the Board of Directors

ABIVAX: Undercovered, Late-Stage French Company With Upcoming Catalysts

ABIVAX Société Anonyme, Annual General Meeting, Jun 06, 2025

ABIVAX Société Anonyme to Report Q1, 2025 Results on Jun 02, 2025

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Abivax SA Announces Resignation of Philippe Pouletty as Director, Effective December 31, 2024

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme to Report Fiscal Year 2023 Results on Apr 02, 2024

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.